Brain-specific homing and direct interactions with the neural substance are prominent hypotheses for brain metastasis formation and a modern manifestation of Paget's ''seed and soil'' concept. However, there is little direct evidence for this ''neurotropic'' growth in vivo. In contrast, many experimental studies have anecdotally noted the propensity of metastatic cells to grow along the exterior of pre-existing vessels of the CNS, a process termed vascular cooption. These observations suggest the ''soil'' for malignant cells in the CNS may well be vascular, rather than neuronal. We used in vivo experimental models of brain metastasis and analysis of human clinical specimens to test this hypothesis. Indeed, over 95% of early micrometastases examined demonstrated vascular cooption with little evidence for isolated neurotropic growth. This vessel interaction was adhesive in nature implicating the vascular basement membrane (VBM) as the active substrate for tumor cell growth in the brain. Accordingly, VBM promoted adhesion and invasion of malignant cells and was sufficient for tumor growth prior to any evidence of angiogenesis. Blockade or loss of the b1 integrin subunit in tumor cells prevented adhesion to VBM and attenuated metastasis establishment and growth in vivo. Our data establishes a new understanding of CNS metastasis formation and identifies the neurovasculature as the critical partner for such growth. Further, we have elucidated the mechanism of vascular cooption for the first time. These findings may help inform the design of effective molecular therapies for patients with fatal CNS malignancies.
Introduction
Brain metastases are the most common malignant tumors of the central nervous system (CNS) outnumbering primary brain tumors such as glioblastoma in prevalence by tenfold [American Cancer Society, http://www.cancer.org/]. Over 20% of all cancer patients develop metastatic disease to the CNS and have a 9 month median survival with maximal treatment [1] [2] [3] [4] . As modern therapies allow improved peripheral control of primary and metastatic disease, such as trastuzumab for metastatic breast cancer, the incidence of brain metastasis appears to be paradoxically increasing [4] [5] [6] [7] . This may be due to several reasons including the blood-brain barrier preventing drug entry, tumor dormancy, positive selection of ''brain-seeking'' or therapyresistant subclones, or iatrogenic induction of new functional mutations. Hence, further characterization of these mechanisms and identification of new strategies for treatment of brain metastasis are important goals.
Clinically, brain metastases most commonly arise from lung, breast, and melano-carcinomas. The major requirements for metastasis to distant sites appear to vary by organ and remain incompletely understood [8] [9] [10] [11] . The pathophysiology of brain metastasis, in particular, remains elusive. In metastasis to lung and bone, characteristic patterns of gene expression in MDA-MB-231-derived mammary carcinoma cells have been shown to enable organ specific colonization [10] . Such factors have not yet been identified for brain metastasis, but are likely to exist as mouse and human carcinoma lines have been selected for increased brain colonization [11, 12] . However, these characterizations of the ''seed'' largely neglect contributions from the ''soil'' and appear to be cell line specific [13] . On the other hand, there is a persistent assumption in the literature that brain metastasis is the result of specific interactions with the neural elements of the brain parenchyma mediating ''brain homing'' (or targeted metastasis to the brain), direct cell attachment and establishment, invasion, and progressive growth into micro-and macrometastases [1, 5, 14, 15] . These ideas are certainly consistent with the classic concept of Pagetian ''soil'', however, there currently exist no in vivo data to support such statements and indeed very few studies address these topics directly. In contrast, we have noted many experimental brain metastasis studies dating back several decades have anecdotally described early growth of tumor cells along pre-existing brain vessels ( [16] [17] [18] [19] [20] [21] [22] ; Table S1 ). This relationship is reminiscent of vascular cooption described in a rat glioma model [23] . These findings suggest the neural elements of the brain parenchyma do not provide a sufficient substrate for metastatic carcinoma growth and instead implicates the existing neurovasculature as a key niche for malignant progression. This also supports the data by Fidler and colleagues [24] that suggests sprouting neoangiogenesis may not be necessary for the initiation of metastasis growth in the brain.
Here, we used a combination of in vitro and in vivo studies and human pathological specimens to analyze the temporospatial growth pattern of brain metastasis microcolonies in order to characterize the relationship between metastatic tumor cells and the existing neurovasculature. We focused on timepoints as early as 3d after intravascular injection in order to focus on the earliest events in microcolony formation. We found that brain micrometastases in mouse and human tissue utilized vascular cooption for growth rather than invading and growing within the neural parenchyma. Vascular cooption can be an alternative to neoangiogenesis and likely acts to deliver blood borne nutrients and oxygen. We propose here that vascular cooption has an additional function for brain metastases; interactions with the pre-existing vessels are required for initial adhesion, proliferation, invasion, and microcolony establishment. We show that the neural parenchyma of the brain cannot substitute in supplying these functions. This work identifies the central role of the vasculature for metastatic growth in the CNS as well as providing insight into the mechanism of adhesive vascular cooption. These novel concepts may allow the development of more effective therapies for brain metastasis.
Results

Perivascular growth of early brain micrometastases in vivo
To characterize the vascular association of tumor cells in experimental brain metastasis models, we examined early brain microcolony formation after intracardiac injection of metastatic mouse and human tumor cells. It has been anecdotally noted that microcolonies in experimental brain metastasis assays often tended to grow along preexisting vessels (Table S1 ). We established that this pattern occurs with a high frequency and across all cell lines we tested. 4T1-GFP mammary carcinoma cells [25] were found to be intimately associated with the perivascular surface of brain microvessels from the earliest timepoint at 3 d up to 14 d (Fig. 1A) after injection into syngeneic BALB/c mice. This was observed in over 97% of the microcolonies at all timepoints (Fig. 1B) . Similar vascular associations resulted from the intracardiac injection of the human breast carcinoma cell lines MDA-MB-231 and its ''brain seeking'' variant cell line MDA231BR [11] , the human melanocarcinoma cell line A7 in SCID mice, and the murine melanoma cell line K1735M2 injected into syngeneic C3H/He mice. Brain microcolonies from each of these cell lines examined between 7 and 14 d after injection were associated with vessels in the same pattern consistent with vascular cooption (Fig. 1C) . Interestingly, the ''brain seeking'' MDA231BR line showed equivalent vascular association and microcolony area as the parental line, although the number of colonies produced by injection of the parental cells was approximately 2 fold less (Fig. S1 ). Thus perivascular colony formation was the predominant pattern of growth by carcinoma cells in experimental in vivo metastasis assays.
We verified that the colonies resulted from proliferation of vascular-associated tumor cells between 3 and 7 d by measuring tumor area (Fig. 1D ) and with BrdU immunohistochemistry (Fig. 1E) . Similar to prior studies [16, 24, 26] , these microcolonies appeared to rely on pre-existing vessels for growth. First, proliferation of tumor cells was observed within 1 week of injection and prior to any evidence of neoangiogenesis (Figs. 1D and 1E). Second, vessel morphology appeared largely normal, however, vessel density was significantly lower in tumor-involved areas of the brain (Fig. S2) . Third, despite the extensive perivascular involvement of the tumors, the endothelial blood brain barrier (BBB) markers GLUT-1 ( Fig. 1F and S2 ) and ZO-1 (not shown) remained unaltered. We verified BBB integrity with static and dynamic studies of function including gadoliniumenhanced MRI (Fig. S2) , small molecular weight TRITC-dextran injection (not shown), and tyramide-signal amplification enhanced immunohistochemistry for IgG extravasation (Fig. S2 ) at timepoints up to 14 d. These results demonstrated that early brain micrometastasis formation was associated with minimal neoangiogenesis leading to the conclusion that growth must be dependent upon pre-existing vessels. Finally, to verify the perivascular preference of brain micrometastases was not biased by intravascular delivery of tumor cells, we characterized a syngeneic model of spontaneous brain metastasis [27] . Brain sections were examined for spontaneous micrometastases 5-7 weeks after orthotopic injection of 4T1-GFP cells into the mammary fat pad (n = 10 mice). The growth and morphological characteristics of these colonies were indistinguishable from those derived from intracardiac delivery of cells demonstrating both intact GLUT-1-positive vasculature and angiotropic spread upon adjacent capillaries (Fig. 1F) .
To assess the clinical relevance of frequent vascular cooption in experimental metastasis, we asked whether tumor cells within human brain metastasis specimens displayed a similar vascular association. In brain micrometastases and tumors with carcinomatous CNS spread that could be considered at the early stages of parenchymal colonization, the patterns were similar to those in the experimental models above, with the tumor cells in these brain metastases appearing to track along the blood vessels ( Fig. 2A) . Quantitation of vascular cooption in these cases from primary tumors of varied origin revealed that 98.2% of metastatic brain colonies were vascular-associated ( Fig. 2B and Table 1 ). Based on clinical pathologic indices, there was little clear morphological evidence characteristic of tumor angiogenesis in these cases (Table 1 and Fig. 2A) . Therefore, early growth of brain metastasis microcolonies in experimental models and human clinical specimens occurs via intimate interactions with the existing neurovasculature. This growth can occur immediately after extravasation (as early as 3 d after intra-arterial injection) and does not require neovascularization.
Vascular cooption after intraparenchymal injection
We further asked whether the association of tumor cells with the vessels was merely a matter of location after extravasation. This was tested by injecting tumor cells directly into the brain allowing equivalent access to both the vascular and the neural elements of the brain. 4T1-GFP cells after intraparenchymal injection formed colonies surrounding vessels within 2 days (Fig. 3A) . 93% of tumor profiles were vascular-associated at 4 d (4T1-GFP cells, n = 3). The apparent increase in the number of tumor cells could not be simply due to migration and homotypic aggregation of the injected tumor cells because BrdU labeling showed widespread proliferation of the tumor cells (Fig. 3A, inset) . Similar results were obtained after intraparenchymal injection of MDA-MB-231 cells (Fig. 3B) . Thus, vascular association or cooption does not rely on cells entering the brain via extravasation from the blood supply and must be due instead to preferential association of the tumor cells with the vessels.
To further these findings, we directly observed tumor cells in vivo using transcranial multiphoton and confocal imaging through a cranial window in mice. This preparation allowed us to serially revisit the same fields through the cranial window from 0 to 4 days following intraparenchymal injection. Injected tumor cells were seen to elongate upon blood vessels within 1 hour of injection (Fig.  S3) . The majority of recently injected cells were spheroidal; after 2 d there was an obvious expansion of tumor cells in the same field (Fig. 3C) . They appeared to be exclusively growing upon vessels ( Figure 3D ). The vascular pattern was not noticeably modified after 2 days and there was no appearance of new vessels consistent with tumor growth dependent upon preexisting vessels. However, some vascular ectasia was noted and possibly associated with greater tumor burden and/or a response to the tissue disruption due to the injection (Fig. 3C, white arrowheads) . These histological and transcranial imaging studies were repeated using direct injection of B16F10-GFP mouse melanoma cells with similar results (Fig. S3) . On the basis of these studies, we conclude that the vascular association of tumor cells in brain colonies is not simply due to the physical association of the tumor cell with the vessel after extravasation, but is based upon preferential interactions with the vessel. Vascular cooption occurs by direct adhesion to vessel wall exterior
We sought to generate experimental situations in tissue culture analogous to the intraparenchymal injections to characterize the interaction of metastatic tumor cells with the vascular or neural elements of the brain. First, we used an ex vivo assay with tumor cells plated onto live, acutely isolated adult mouse brain slices [28] . All five of the murine and human tumor lines tested for experimental brain metastasis in Fig. 1 were plated on live slices. Each of these cell lines was found to preferentially elongate upon the vasculature within 2 hours (Fig. 4A , 4B and S4). Tumor cells not directly in contact with vessels did not spread ( Fig. 4A and S4 ). These results were directly verified with timelapse confocal microscopy (Movie S1). Thus, we concluded that metastatic carcinoma cells, when given equal access to live vascular and neural substrates, interact preferentially with the vessels over the neural parenchymal elements.
Based on morphological features of cells and microcolonies in histological sections (Figs. 1 and 2) and the rapid cell spreading on live slices observed above, we reasoned that there was likely an active adhesive interaction between the metastatic tumor cells and the exterior of blood vessels. To test the potential for tumor cell adhesion to elements of the brain parenchyma, either vascular or neural, we assayed adhesion of metastatic tumor cells plated on thawed slide-mounted snap frozen brain sections. 4T1-GFP cells were plated on normal murine brain and cultured for 2 h followed by washing off non-adherent cells. Only a small minority of plated cells adhered to the slices, however, 93% of these adherent cells were in contact with vessels ( Fig. 4C) . To test the adhesion of human tumor cells, we used the MDA-MB-231 breast carcinoma line in a parallel assay with human brain sections. Similarly 85% of the adherent human cells were associated with vessels ( Fig. 4D and  S5 ). These results demonstrated that metastatic tumor cells adhere to the brain parenchyma and that their preferred substrate is vascular rather than neural. These studies complement the observations in live slices that showed tumor cell spreading to be associated with vascular, not parenchymal engagement.
Vascular cooption promotes CNS invasion of metastatic cells
The preferential vessel adhesion and spreading of metastatic tumor cells raised the possibility that invasion might also depend upon the vasculature. To determine whether metastatic tumor invasion required vessels or could occur via neural elements, we modeled vascular invasion in vitro by plating 4T1-GFP spheroids on live post-natal brain slices. After 3 to 7 days of co-culture, Table 1 ) demonstrates vascular association. Right, high power view of hatched region. Scale bars, 0.5 mm (left), 120 mm (right). (B) Quantitation of vascular association in human brain metastasis specimens of diverse primary origin from six patients (*P,0.001, t-test, n = 3420 tumour profiles from 6 patients; Table 1 spheroids invaded the slice almost exclusively upon the vascular scaffolding ( Fig. 5A and 5B). Spheroids that failed to contact vessels showed little evidence of invasion into the brain slice ( Fig. 5A , right). The importance of vascular contact for invasion was confirmed by measuring the depth of penetration into the slices. The spheroids in contact with the vessels penetrated significantly deeper into the brain slice than those without contact (Fig. 5C ). Thus, invasion of carcinoma cells in the brain parenchyma preferentially involves vascular interactions. Histological examination of the edges of the tumor masses from microcolonies in the spontaneous, intracardiac injection, and intraparenchymal models provided additional evidence for the predominant association of invasion with vessels. The leading edge from these tumors consisted of collective extensions/protrusions of tumor cells growing along adjacent vasculature (Figs. 1A, 1F , 3A, 3B, and S3; arrows). Collective angiotropic invasion was verified in the 4T1-GFP and B16F10-GFP models in vivo with transcranial imaging (Fig. 3D and S3 ). Human brain metastasis specimens were similarly examined for evidence of vascular associated parenchymal invasion. In 80% (8 of 10) cases of wellestablished solitary CNS breast cancer metastases, we could identify at least one area at the tumor-brain interface consistent with collective angiotropic invasion (Fig. 5D) . Additionally, vascular association was observed in specimens showing single cell invasion (Fig. 5E) . Finally, vascular-dependent invasion from the Virchow-Robin spaces was observed identically in both the mouse model and in carcinomatous human specimens (Fig. 5F ). Therefore, metastatic carcinoma cells have limited ability to infiltrate neural substrates in vivo; instead, parenchymal invasion occurs predominantly via the vasculature consistent with an adhesive reliance on blood vessels.
Adhesion to VBM promotes growth of metastatic cells
The substrate for adhesion of carcinoma cells to brain vessels is likely the vascular basement membrane (VBM) which is composed predominantly of collagen type IV and laminins. Consistent with this hypothesis, the spatial distribution of collagen types I and IV, entactin fibronectin, laminin, and perlecan is limited to the exterior of blood vessels in the brain parenchyma (Fig. S6) . These basement membrane proteins are known to promote anchoragedependent growth signaling of adherent cells and are widely used to coat dishes for culture. To test the role of brain VBM in tumor cell growth signaling we examined whether adhesion to VBM components could potentiate metastatic cell proliferation in vitro in the absence of serum. 4T1-GFP cells were plated on collagen I, collagen IV, fibronectin, laminin, vitronectin, or BSA-coated control wells in the absence of serum. Cellular proliferation was measured at 48 h by BrdU incorporation ELISA. 4T1-GFP cells demonstrated significantly increased BrdU incorporation on all substrata compared to BSA (Fig. 6A) . Consistent with the role of ERK in anchorage-dependent signaling for cellular survival and growth, this potentiation could be attenuated with incubation with the highly specific MEK inhibitor, SL327. Similar results were obtained with MDA-MB-231 and B16F10-GFP cells (Results not shown). Therefore, individual components of VBM are sufficient to support significant proliferation of metastatic tumor lines in the absence of serum in vitro.
We sought to verify that anchorage-dependent growth signaling from the VBM was a significant contribution to tumor growth in vivo. In order to distinguish use of the VBM from those growth signals and nutrients delivered directly from the bloodstream, we tested whether non-perfused vessels could act as sites for vascular cooption and tumor growth. Blood vessels were microdissected from the brain surface and placed upon the site of intraparenchmal tumor cell injection before implantation of a cranial window. Serial transcranial imaging was then performed to monitor tumor growth at 0, 2, and 4 days ( Fig. 6B and results not shown). Widespread angiotropic growth and invasion occurred along the exterior of non-perfused vessels within just 2 d in 4 of 4 mice (Fig. 6C ). This experiment suggests that adhesion to VBM of non-perfused vessels can promote vascular cooption and early growth of metastatic cells in the brain in vivo.
The mechanism of vascular cooption in the CNS
We have shown that the vascular association of tumor cells in the CNS is based on adhesion to the VBM and that this relationship supports establishment and progression of tumor microcolonies independent of blood-born nutrients. Since cellular adhesion to vascular basement membrane components requires members of the integrin family of cellular adhesion receptors [29] , it is likely that vascular cooption and subsequent metastatic tumor growth in the brain relies on identical mechanisms. As a corollary, we found marked immunoreactivity for activated focal adhesion kinase (pFAK-Y397), a major integrin signaling pathway, in 4T1-GFP microcolonies in vivo (Fig. S7) . To test this hypothesis directly we investigated the effect of blocking integrin function on adhesion and metastatic colony growth. We focused this series of experiments on the human breast carcinoma line MDA-MB-231 because the integrin complement in this cell line has been well characterized [30] and due to the wider array of effective antiintegrin blocking antibodies available for human than for mouse. First, we confirmed expression of various integrin subunits on MDA-MB-231 microcolonies in vivo (Fig. S7) as previously described in vitro [30] . We next tested integrin subunit blocking antibodies on attachment to ECM in tissue culture. The antib1integrin subunit antibody alone nearly completely blocked adhesion of MDA-MB-231 cells to various types of ECM whereas antibodies to any other single a or b subunit did not similarly block adhesion (Fig. S7) . Given the known functional redundancy in the complement of b1 integrins and the dominant role for b1 signaling in adhesion, migration and proliferation [31] , this is not a surprising result. Indeed, all cell lines used in this study expressed high levels of b1 integrins (Fig. S7 and results not shown) .
To test the importance of b1 integrins in brain metastasis, we assayed tumor cell adhesion on a more physiologically-relevant substrate using brain sections. MDA-MB-231 cells were preincubated with either isotype-matched IgG1 control or anti-b1 activating or inhibiting antibodies prior to plating on adjacent unfixed slide-mounted human brain sections (Fig. 7A) . The tumor cells when plated on brain sections had been noted to adhere almost exclusively to vessels (Fig. 4C and 4D ). Adhesion to vessels was potentiated by anti-b1 integrin activating antibodies and markedly attenuated by anti-b1 integrin blocking antibody (Fig. 7A  and 7B ). Thus, adhesion of tumor cells to the VBM, and consequently the process of vascular cooption, depends upon tumor cell b1 integrins.
To investigate the relevance of the above findings in vivo we asked whether blocking the b1 integrin subunit would affect colony formation after intraparenchymal injection of tumor cells. MDA-MB-231 cells were incubated with monoclonal antibodies which block the function of the human, but not murine, b1 integrin subunit (Results not shown). Axial tumor area was evaluated 4 d after the injection on histopathology (Fig. 7C) . As predicted, the brain colonies derived from cells treated with non- blocking antibodies were significantly larger than those from the cells treated with blocking antibodies (Fig. 7D) . We verified the antibody treatment itself was not toxic to these tumor cells after culture in the absence of serum and ECM substrate (Results not shown). Thus, cells treated with b1 integrin subunit blocking antibodies largely failed to become established and grow in the brain consistent with the inability to adhere to and utilize the surrounding blood vessels.
Brain metastasis establishment requires b1 integrinmediated proliferation
The above results with function blocking antibodies identify an important role for b1 integrins in metastatic tumor microcolony establishment in the CNS. To further evaluate the effect of b1 integrins on colony formation, we analyzed CNS growth of ESb murine lymphoma cells and of an engineered mutant in which the b1 integrin subunit has been genetically eliminated (ESb-DKO) [32] . Both ESb and ESb-DKO cells proliferate normally in suspension in vitro under standard defined medium conditions ( [32] and Results not shown) and are not susceptible to anoikis. Similar to the pathology seen in many human lymphomas, and in contrast to that of carcinoma metastases, ESb cells diffusely invaded through the parenchyma, but demonstrated superimposed perivascular cuffing reminiscent of cooption (Fig. 8A) . These cells formed a rapidly growing lesion often measuring over a millimeter in diameter in just 4 d. In contrast, the b1 integrin subunit deficient ESb-DKO cells were significantly impaired in the ability to grow and form an expanding lesion in the brain (Fig. 8B and  8C ). ESb-DKO cells retained the capability for invasion deep into the brain parenchyma confirming that the b1 integrin subunit is not necessary for lymphoma invasion of the CNS [33] (Fig. 8B,  arrows) . We noted a low baseline of BrdU+ profiles at the injection site of mice and widespread invasion and BrdU-positive cells throughout the cranial fascia and dermis overlying the injection site in mice injected with ESb-DKO ruling out a proliferative defect in the mutant line in vivo (Fig. S8) [32] .
To verify that ESb cells interacted with the VBM in vivo, we analyzed tissue sections with immunohistochemistry against activated focal adhesion kinase (pFAK-Y397) and activated extracellular regulated kinase (pERK1/2). ESb cells were highly immunoreactive for pFAK-Y397 confirming integrin-mediated anchorage-dependent signaling (Fig. 8D) . In contrast, ESb-DKO cells demonstrated only background levels of immunoreactivity for pFAK-Y397. ERK activity is downstream of FAK activation and associated with survival and mitosis. We observed strong nuclear and moderate cytoplasmic pERK1/2 immunoreactive ESb lymphoma cells, but only weakly positive ESb-DKO cells in brain colonies (Fig. 8E) . In addition, ESb-colonized vessels demonstrated frequent perivascular BrdU positive nuclei (Fig. 8F, inset) . Interestingly the majority of BrdU+ cells (67%) were found in direct contact or within 10 mm of vessels (Fig. 8E) . Therefore, ESb, but not ESb-DKO, tumor cells in the brain were associated with immunoreactivity for activated FAK and ERK as well as perivascular BrdU consistent with proliferation via anchorage dependent signaling from the VBM. Thus, the b1 integrin subunit on tumor cells mediates anchorage-dependent growth signaling upon adhesion to the VBM of the neurovasculature and is essential for the formation of metastatic brain colonies by ESb cells. Further, the requirement for the b1 integrin subunit is independent from protection from anoikis in this case.
Discussion
We have demonstrated that the primary soil for metastatic tumor cell attachment and growth in the brain is vascular rather than neural. This vascular cooption, or the utilization of preexisting vessels, has only been previously anecdotally reported as a form of vascularization in experimental brain metastasis (Table  S1 ). Here, we have quantitatively demonstrated it to be the predominant form of vessel use by tumor cells during early experimental brain metastasis establishment and in human clinical specimens reflecting early stages of the disease. We further show the interaction relies on b1 integrin-mediated tumor cell adhesion to the vascular basement membrane of blood vessels. These findings exclude a requirement for de novo angiogenesis prior to microcolony formation. They also contrast with the classical seed and soil hypothesis for brain metastasis suggesting a neural substrate and reliance upon neural-derived trophic factors for growth. Importantly, they do not exclude vascular remodeling [24] or contributions from the neural elements for later growth [34] . This work thus describes in detail a major mechanism of brain metastasis formation in addition to identifying the mechanism of vessel cooption in the brain for the first time.
The CNS parenchyma is largely devoid of non-vascular stromal basement membrane components which are necessary for epithelial and carcinoma cell adhesion and survival (Fig. S6) . Vascular cooption, therefore, supplies substrates for malignant growth of non-neural carcinoma cells not otherwise widely available in the neuropil. Proliferation by metastatic tumor cells is highly potentiated upon adhesion to a basement membrane substratum and is attenuated by inhibiting MEK in vitro. Consistent with the experiments in tissue culture, during the early stages of colony formation in vivo we found the vast majority of micrometastases to be in direct contact with the VBM of existing brain vessels and many of these cells were proliferating.
Resident neural stem cells tend to localize in perivascular locations [35] and cells defined as brain tumor stem cells (BTSCs) are found in a similar location [36, 37] . Secreted paracrine growth factors from the endothelial cells of the ''perivascular niche'' were shown to stimulate the growth and survival of BTSCs. In contrast, we demonstrated that slide-mounted brain sections (i.e., dead tissue) still supplied the components needed for adhesion and spreading by carcinoma cells. The requirement of metastatic carcinoma cells for the vasculature in adhesion and invasion during metastasis in the brain may be more analogous to the requirement for VBM during development of pancreatic islets [38] . Islet cells use b1 integrins to interface with the VBM and this interaction is required for proliferation and endocrine function. Nikolova et al. termed this basement membrane microenvironment, a ''vascular niche'' [38, 39] . Similarly vascular mural cells require the b1 integrin subunit for proper adhesion to vessels and for maintaining vessel stability [40] . In an analogous fashion, carcinoma cells, then, appear to hijack the brain's VBM for essential functions during brain metastasis. Interestingly, inhibiting angiogenesis in circumscribed, well-established CNS melanoma metastases causes reversion to growth by vascular cooption [19] . This suggests a continuum for vessel utilization by tumor cells which may represent a viable target for therapeutic exploitation.
The interaction between the tumor cells and the vessels relies on b1 integrin-mediated tumor cell adhesion to the vascular basement membrane of blood vessels. This interaction is sufficient to promote immediate proliferation and micrometastasis establishment of tumor lines in the brain. This angiotropic mechanism was universal to both carcinomas (anchorage-dependent cells) and lymphomas (anchorage-dispensible cells) in the CNS. b1 integrins play a dominant role in many facets of normal cell biology and have been implicated in cancer initiation, progression, and metastasis [30] [31] [32] [41] [42] [43] [44] . There are at least 10 b1 integrin heterodimers which serve as variably promiscuous adhesive receptors to diverse ligands such as the collagens and laminins. Nonetheless our data suggest that antagonism of the b1 integrin subunit alone might be useful in therapeutic strategies for brain metastases. Indeed, Park et al [42] found that inhibitory anti-b1 integrin subunit antibodies induced apoptosis in breast carcinoma cells grown in three dimensional culture, but not in cells grown in monolayers. Treating mice bearing breast cancer xenografts from those cell lines with the same antibody led to decreased tumor volume. In addition to the apoptotic mechanism described in vitro, inhibition of vascular cooption may have also attenuated growth. In an alternative strategy to evaluate the role of b1 integrins, tumors were analyzed in the MMTV/PyMT transgenic model of breast cancer [43] . Conditional deletion of b1 integrin after induction of tumorigenesis resulted in impairment of FAK phosphorylation and proliferation consistent with a reliance on anchorage-dependent signaling for tumor growth. Although the presence of the b1 integrin subunit is mandatory for embryonic development, chronic systemic anti-b1 antibody therapy did not result in overt toxicities in adult mice [42] . Further research into the regulation of b1 integrin regulation, function and downstream signaling may yield clinically useful applications for metastatic disease in cancer patients [31, 45, 46] .
Materials and Methods
Ethics statement
Animal procedures were performed under UK Home Office licensing and ethics committee approval from the Clinical Medicine Ethical Review Committee at the University of Oxford. Human tissue was retrieved from the Thomas Willis Oxford Brain Collection with prior written informed consent and final approval from the local research ethics committee (reference 06/Q1604/ 141).
In vivo experiments
All animal procedures were approved by the UK Home Office. Experimental brain metastases were established by intracardiac injection of 10 5 tumor cells [11] . Alternatively, direct intraparenchymal injection of 5610 3 to 10 4 cells was performed into the striatum or hippocampus with a stereotaxic apparatus (Benchmark, MyNeurolab.com). MRI imaging was performed with a 7-Tesla horizontal bore magnet with a Varian Inova spectrometer (Varian) between 2 and 14 d post tumor inoculation. Transcranial imaging was performed up to 3 times via cranial window with a Leica TCS-SP2 AOBS confocal microscope and a Spectra-Physics MaiTai Ti-Sapphire pulsed laser.
In vitro experiments
VBM adhesion and proliferation assays were performed with 10 mg/ml ECM components or BSA (control). Adhesion was tested after 2 h and proliferation after 48 h. Adhesion to brain sections was evaluated after 2 h [28] . Non-adherent cells were rinsed off in three rinses of PBS on a shaker set. Live brain slice assays were performed acutely for 2 hours or 3 to 7 d for long-term culture as described in Text S1.
Human specimens
Clinical neuropathology specimens were obtained with ethics committee approval from routine neurosurgical or autopsy procedures and processed for routine immunohistochemistry and analyzed as described in Text S1.
Integrin inhibition studies
Inhibitory monoclonal antibodies against integrin subunits and isotype control antibodies were used at 5 to 20 mg/ml.
Histological analysis
Experimental tissues were collected under terminal anesthesia after transcardiac perfusion with saline and 4% paraformaldehyde or organs were freshly isolated and snap frozen or immersion fixed. Immunohistochemistry was performed as described in Text S1 in 15-30 mm cryostat sections.
Statistical analyses
Data were compiled in MS Excel and data analyzed with Excel or Graph Pad InStat 3. Pairwise comparisons were made with an unpaired t-test or the Mann-Whitney u-test as appropriate. Evaluation of variance in data groups was performed with ANOVA or the Kruskal-Wallis test as appropriate. If significance was detected post-hoc comparisons were made with an appropriate post-hoc test. A p,0.05 was considered statistically significant.
For detailed methodology please see Text S1.
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